Archive · 21 Jul 2026
FDA Approves First Oral PCSK9 Drug for High Cholesterol
The FDA has approved a new medicine called Lipfendra, which is a pill that helps lower bad cholesterol in the blood.
This is important because high cholesterol can cause problems like heart attacks and strokes.
Lipfendra works by blocking a protein that stops the liver from cleaning out bad cholesterol.
It is meant for adults who have high cholesterol even after trying diet, exercise, and other medicines.
The medicine was tested on over 3,200 people and was found to lower bad cholesterol by about 56-59%.
While it is generally safe, some people might feel dizzy or have diarrhea.
Doctors say it is important to keep taking the medicine as directed and to also maintain a healthy lifestyle.
FDA approves Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol.
Lipfendra is intended for adults with high cholesterol and heterozygous familial hypercholesterolaemia (HeFH).
Clinical trials showed Lipfendra reduces LDL cholesterol by 56-59%.
Common side effects include diarrhea and dizziness.
Lipfendra is not a replacement for a healthy lifestyle but should complement it.
- Who
- Adults with high cholesterol and heterozygous familial hypercholesterolaemia (HeFH)
- What
- FDA approval of Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol
- When
- July 21, 2026
- Where
- United States
- Why
- To provide an alternative treatment for patients who do not respond to statins or cannot tolerate injectable PCSK9 inhibitors
Proponents of Lipfendra
Skeptics of Lipfendra
Effectiveness
Proponents of Lipfendra
Lipfendra significantly reduces LDL cholesterol, offering a new treatment option for patients who do not respond to statins or cannot tolerate injectable PCSK9 inhibitors.
Skeptics of Lipfendra
While Lipfendra shows promise in lowering cholesterol, long-term studies are needed to confirm its impact on cardiovascular outcomes and overall heart health.
Convenience
Proponents of Lipfendra
The oral form of Lipfendra provides a more convenient alternative to injectable PCSK9 inhibitors, potentially improving patient compliance.
Skeptics of Lipfendra
The convenience of an oral medication may lead to over-reliance on medication, potentially discouraging patients from maintaining a healthy lifestyle.
- Drug Name
- Lipfendra (enlicitide)
- Approval Date
- July 21, 2026
- Target Protein
- PCSK9
- Clinical Trial Participants
- 3,200+
- LDL Cholesterol Reduction
- 56-59%
- Common Side Effects
- Diarrhea, Dizziness
- Intended Use
- Adults with high cholesterol and heterozygous familial hypercholesterolaemia (HeFH)